English

Celldex Therapeutics, Inc.

EDGAR

CLDX Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2025: about Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 1.545M, using the latest reported figures. The previous period, 2024, was about Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 7.02M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

22 thousand Unit_Standard_USD_SCRLz_kx6USKp5NArfp8-A

2026 Q2 · Unit_Standard_USD_SCRLz_kx6USKp5NArfp8-A

Exact inputs and evidence

Revenue: 22000 Unit_Standard_USD_SCRLz_kx6USKp5NArfp8-A Source

Operating margin

-366,468.18%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -80623000 Unit_Standard_USD_SCRLz_kx6USKp5NArfp8-A Source
Revenue: 22000 Unit_Standard_USD_SCRLz_kx6USKp5NArfp8-A Source

Cash and cash equivalents: 47.5 million Unit_Standard_USD_SCRLz_kx6USKp5NArfp8-A 2026-06-30 Source
Exact value

47454000 Unit_Standard_USD_SCRLz_kx6USKp5NArfp8-A
Long-term debt including current maturities: Not available
Shares outstanding: 78.5 million Unit_Standard_shares_hHAmWSGHxkqWjED8NVjTfA 2026-06-30 Source
Exact value

78500173 Unit_Standard_shares_hHAmWSGHxkqWjED8NVjTfA

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-78%

Prior period

Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 7.02 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 1.55 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1545000 − 7020000 = -5475000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg

7020000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1545000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Celldex Therapeutics, Inc. · 2025-12-31 Celldex Therapeutics, Inc. (edgar:744218) Year-over-year change in Revenue: -5475000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1545000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1351200 Filing: 000110465926019652 Input fundies:Revenue: 7020000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1352264 Filing: 000110465926019652
The citation records this snapshot. The page link may show a newer release later.
Net income
−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 100.94 million

Prior period

−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 157.86 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 258.8 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-258800000 − -157863000 = -100937000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg

-157863000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-258800000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Celldex Therapeutics, Inc. · 2025-12-31 Celldex Therapeutics, Inc. (edgar:744218) Year-over-year change in Net income: -100937000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -258800000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1637164 Filing: 000110465926019652 Input fundies:NetIncome: -157863000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1499244 Filing: 000110465926019652
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 53.12 million

Prior period

−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 157.78 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 210.9 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-210900000 − -157778000 = -53122000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg

-157778000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-210900000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Celldex Therapeutics, Inc. · 2025-12-31 Celldex Therapeutics, Inc. (edgar:744218) Year-over-year change in Operating cash flow: -53122000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -210900000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1637567 Filing: 000110465926019652 Input fundies:OperatingCashFlow: -157778000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1588733 Filing: 000110465926019652
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+41.4%

Prior period

Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 1.92 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2.71 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

2714000 − 1919000 = 795000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg

1919000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
2714000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Celldex Therapeutics, Inc. · 2025-12-31 Celldex Therapeutics, Inc. (edgar:744218) Year-over-year change in Capital expenditure: 795000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2714000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1600045 Filing: 000110465926019652 Input fundies:CapitalExpenditure: 1919000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1601074 Filing: 000110465926019652
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 1.55 million 100% of revenue
Operating costs Derived Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 288.91 million 18,700% of revenue
Operating income −Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 287.37 million −18,600% of revenue
Tax, interest and other Derived −Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 28.57 million −1,849% of revenue
Net income −Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 258.8 million −16,751% of revenue

Cash

Operating cash flow −Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 210.9 million −13,650% of revenue
Capital expenditure Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2.71 million 176% of revenue
Free cash flow Derived −Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 213.61 million −13,826% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Operating loss: operating costs were 2,345% of revenue.
2024 Operating loss: operating costs were 2,879% of revenue.
2025 Operating loss: operating costs were 18,700% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	6883000	161425000 Derived	-154542000	-13113000 Derived	-141429000	-109109000 Derived	Source 2023-01-01 – 2023-12-31: 6883000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Revenue Open source 2023-01-01 – 2023-12-31: -154542000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -141429000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Net Income Open source 2023-01-01 – 2023-12-31: -107291000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 1818000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	7020000	202098000 Derived	-195078000	-37215000 Derived	-157863000	-159697000 Derived	Source 2024-01-01 – 2024-12-31: 7020000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Revenue Open source 2024-01-01 – 2024-12-31: -195078000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -157863000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Net Income Open source 2024-01-01 – 2024-12-31: -157778000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1919000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	1545000	288912000 Derived	-287367000	-28567000 Derived	-258800000	-213614000 Derived	Source 2025-01-01 – 2025-12-31: 1545000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Revenue Open source 2025-01-01 – 2025-12-31: -287367000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -258800000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Net Income Open source 2025-01-01 – 2025-12-31: -210900000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 2714000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 1.5M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg)	Source evidence
20232023-12-31	Revenue	6883000	Revenue: 6883000 Open source
20242024-12-31	Revenue	7020000	Revenue: 7020000 Open source
20252025-12-31	Revenue	1545000	Revenue: 1545000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-78% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 6883000 Open source
20242024-12-31	Year over year	2%	Revenue: 7020000 Open source Revenue: 6883000 Open source
20252025-12-31	Year over year	-78%	Revenue: 1545000 Open source Revenue: 7020000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -18,599.8% 2025

Net margin -16,750.8% 2025

Free cash flow margin -13,826.1% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	-2,245.3%	Operating Income: -154542000 Open source Revenue: 6883000 Open source
20242024-12-31	Operating margin	-2,778.9%	Operating Income: -195078000 Open source Revenue: 7020000 Open source
20252025-12-31	Operating margin	-18,599.8%	Operating Income: -287367000 Open source Revenue: 1545000 Open source
20232023-12-31	Net margin	-2,054.8%	Net Income: -141429000 Open source Revenue: 6883000 Open source
20242024-12-31	Net margin	-2,248.8%	Net Income: -157863000 Open source Revenue: 7020000 Open source
20252025-12-31	Net margin	-16,750.8%	Net Income: -258800000 Open source Revenue: 1545000 Open source
20232023-12-31	Free cash flow margin	-1,585.2%	Revenue: 6883000 Open source Operating Cash Flow: -107291000 Open source Capital Expenditure: 1818000 Open source
20242024-12-31	Free cash flow margin	-2,274.9%	Revenue: 7020000 Open source Operating Cash Flow: -157778000 Open source Capital Expenditure: 1919000 Open source
20252025-12-31	Free cash flow margin	-13,826.1%	Revenue: 1545000 Open source Operating Cash Flow: -210900000 Open source Capital Expenditure: 2714000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg -210.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg)	Source evidence
20232023-12-31	Operating cash flow	-107291000	Operating Cash Flow: -107291000 Open source
20242024-12-31	Operating cash flow	-157778000	Operating Cash Flow: -157778000 Open source
20252025-12-31	Operating cash flow	-210900000	Operating Cash Flow: -210900000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg -213.6M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg)	Source evidence
20232023-12-31	Free cash flow	-109109000	Operating Cash Flow: -107291000 Open source Capital Expenditure: 1818000 Open source
20242024-12-31	Free cash flow	-159697000	Operating Cash Flow: -157778000 Open source Capital Expenditure: 1919000 Open source
20252025-12-31	Free cash flow	-213614000	Operating Cash Flow: -210900000 Open source Capital Expenditure: 2714000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Liabilities / assets	Not reported	No source recorded
2024-12-31	Liabilities / assets	Not reported	No source recorded
2025-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2024-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 141.43 million Exact value Exact value: -141429000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2023-01-01 – 2023-12-31: -141429000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Net Income Open source Share or cite Citation for Net Income · Celldex Therapeutics, Inc. · 2023-12-31 Celldex Therapeutics, Inc. (edgar:744218) Net Income: -141429000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg&dimensions= Input fundies:NetIncome: -141429000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1464825 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 107.29 million Exact value Exact value: -107291000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2023-01-01 – 2023-12-31: -107291000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Celldex Therapeutics, Inc. · 2023-12-31 Celldex Therapeutics, Inc. (edgar:744218) Operating Cash Flow: -107291000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg&dimensions= Input fundies:OperatingCashFlow: -107291000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1589773 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 1.82 million Exact value Exact value: 1818000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2023-01-01 – 2023-12-31: 1818000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Celldex Therapeutics, Inc. · 2023-12-31 Celldex Therapeutics, Inc. (edgar:744218) Capital Expenditure: 1818000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg&dimensions= Input fundies:CapitalExpenditure: 1818000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1602103 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 109.11 million Calculation and evidence -107291000 − 1818000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Exact free cash flow: -109109000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2023-01-01 – 2023-12-31: -107291000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1818000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Celldex Therapeutics, Inc. · 2023-12-31 Celldex Therapeutics, Inc. (edgar:744218) Free cash flow: -109109000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -107291000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1589773 Filing: 000110465926019652 Input fundies:CapitalExpenditure: 1818000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1602103 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 157.86 million Exact value Exact value: -157863000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2024-01-01 – 2024-12-31: -157863000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Net Income Open source Share or cite Citation for Net Income · Celldex Therapeutics, Inc. · 2024-12-31 Celldex Therapeutics, Inc. (edgar:744218) Net Income: -157863000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg&dimensions= Input fundies:NetIncome: -157863000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1499244 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 157.78 million Exact value Exact value: -157778000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2024-01-01 – 2024-12-31: -157778000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Celldex Therapeutics, Inc. · 2024-12-31 Celldex Therapeutics, Inc. (edgar:744218) Operating Cash Flow: -157778000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg&dimensions= Input fundies:OperatingCashFlow: -157778000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1588733 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 1.92 million Exact value Exact value: 1919000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2024-01-01 – 2024-12-31: 1919000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Celldex Therapeutics, Inc. · 2024-12-31 Celldex Therapeutics, Inc. (edgar:744218) Capital Expenditure: 1919000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg&dimensions= Input fundies:CapitalExpenditure: 1919000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1601074 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 159.7 million Calculation and evidence -157778000 − 1919000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Exact free cash flow: -159697000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2024-01-01 – 2024-12-31: -157778000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1919000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Celldex Therapeutics, Inc. · 2024-12-31 Celldex Therapeutics, Inc. (edgar:744218) Free cash flow: -159697000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -157778000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1588733 Filing: 000110465926019652 Input fundies:CapitalExpenditure: 1919000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1601074 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 258.8 million Exact value Exact value: -258800000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2025-01-01 – 2025-12-31: -258800000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Net Income Open source Share or cite Citation for Net Income · Celldex Therapeutics, Inc. · 2025-12-31 Celldex Therapeutics, Inc. (edgar:744218) Net Income: -258800000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg&dimensions= Input fundies:NetIncome: -258800000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1637164 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 210.9 million Exact value Exact value: -210900000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2025-01-01 – 2025-12-31: -210900000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Celldex Therapeutics, Inc. · 2025-12-31 Celldex Therapeutics, Inc. (edgar:744218) Operating Cash Flow: -210900000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg&dimensions= Input fundies:OperatingCashFlow: -210900000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1637567 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2.71 million Exact value Exact value: 2714000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2025-01-01 – 2025-12-31: 2714000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Celldex Therapeutics, Inc. · 2025-12-31 Celldex Therapeutics, Inc. (edgar:744218) Capital Expenditure: 2714000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg&dimensions= Input fundies:CapitalExpenditure: 2714000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1600045 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 213.61 million Calculation and evidence -210900000 − 2714000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Exact free cash flow: -213614000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg 2025-01-01 – 2025-12-31: -210900000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 2714000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Celldex Therapeutics, Inc. · 2025-12-31 Celldex Therapeutics, Inc. (edgar:744218) Free cash flow: -213614000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T22:59:48Z Snapshot: b8d24cc93143fd2b629e5253483795aeb81874cc5353ae89cc28b42680ea127b Dimensions: Consolidated View: https://fundies.io/companies/edgar/744218?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -210900000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1637567 Filing: 000110465926019652 Input fundies:CapitalExpenditure: 2714000 Unit_Standard_USD_VsNBfA4G306RHACg-j7qUg (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm#1600045 Filing: 000110465926019652 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

149 filings · 4,950 latest values · 4,950 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000744218, 744218, CLDX, edgar:744218

Also known as AVANT IMMUNOTHERAPEUTICS INC, CELLDEX THERAPEUTICS, INC., Celldex Therapeutics, Inc., T CELL SCIENCES INC

Celldex Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation